Showing results (251-260 of 270) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2024
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient TumorsBrian M Slomovitz, David Cibula, Weiguo Lv, et al.
Tumori|December 15, 2025
Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trialAlessio Carbone, Elena Biagioli, Vanda Salutari, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 13, 2020
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panelDomenica Lorusso, Alessandra Bologna, Sabrina Chiara Cecere, et al.
Critical Reviews in Oncology/Hematology|June 8, 2025
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus reportFederica Miglietta, Maria Grazia Razeti, Aldo Caltavituro, et al.
Journal of the National Cancer Institute|May 1, 2019
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Tomás Pascual, Carmine De Angelis, et al.
NPJ Breast Cancer|April 17, 2023
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitorsEmma Zattarin, Daniele Presti, Luigi Mariani, et al.
The New England Journal of Medicine|January 15, 2025
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast CancerCharles E Geyer, Michael Untch, Chiun-Sheng Huang, et al.
Breast Cancer Research and Treatment|November 10, 2021
Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety: a multicenter Italian retrospective studyMarco Klinger, Agnese Losurdo, Andrea V E Lisa, et al.
The Lancet. Oncology|November 5, 2020
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, Valentina Guarneri, Laia Paré, et al.
Breast (Edinburgh, Scotland)|April 28, 2026
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 studyFrancesca Ligorio, Leonardo Provenzano, Giuseppe Fotia, et al.
Pageof 27